VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from inflammatory and fibrotic diseases. Their lead drug candidate, VISN-101, is a novel small molecule inhibitor targeting a key pathway implicated in these conditions. The company aims to address significant unmet medical needs in areas like idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders.